Audio Broadcast - BV Efficacy Trial Results
Starpharma invites you to listen to an audio broadcast with Chief Executive Officer Dr Jackie Fairley, regarding the successful results of the major phase 2 clinical study that demonstrated efficacy of VivaGel® for the treatment of bacterial vaginosis (BV).
To listen to the Boardroom Radio audio broadcast please click here.
VivaGel® Demonstrates Efficacy in Bacterial Vaginosis
Starpharma today announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel® for the treatment of bacterial vaginosis (BV).
Key Points:
- VivaGel® meets primary endpoint, demonstrating significant efficacy for treatment of BV
- VivaGel® expected to avoid many shortcomings of existing therapies
VivaGel® Coated Condom: Licence Agreement for Japan with Okamoto
Starpharma today announced that it has signed a licence agreement with Okamoto Industries Inc in relation to the VivaGel®-coated condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market.